Steven Engle, CEO

Oct. 11 | 5:30pm | Oxford Biomedica Ballroom  

Dallas, TX 


In-person Presentation 

Gradalis is a late-stage biotechnology company preparing to initiate a Phase III registration study in patients with ovarian cancer using a breakthrough immunotherapy platform. Based on multiple clinical studies, Gradalis has demonstrated that its immunotherapy platform decloaks the full repertoire of a patient’s tumor antigens, reactivates the immune system, and summons key effector cells to deliver a durable clinical response. When combined, these form a powerful trifecta of anti-cancer activities, potentially eliminating even the elusive metastatic cells, and as shown in Phase II clinical studies in ovarian cancer, a potential game changer in oncology. In addition, multiple clinical trials have demonstrated that Gradalis’ platform is better tolerated compared to standard cancer treatments. This is not a surprise since the platform uses the patient’s immune system operating with its natural state of balance rather than in an artificial overdrive as with some technologies 

By using this website you agree to accept our Privacy Policy and Terms & Conditions